According to FutureWise analysis the market for downstream bioprocessing controllers in 2023 is US$ 1.39 billion, and is expected to reach US$ 5.05 billion by 2031 at a CAGR of 17.50%.
Rising insistence for biopharmaceuticals, increased acceptance of single-use technology, expansion of the capacity by the companies manufacturing biopharmaceutical products are some of the key factors driving the market growth. Furthermore, rising penetration of large molecules and biologics shall increase the acceptance of downstream methods, thereby proliferating the market. Purity, reasonable unit cost and efficacy are some of the key parameters to be considered for producing drugs. Downstream technique is often used in both industrial as well as lab applications due to an escalated insistence for biologics, which shall augment the downstream bioprocessing controllers market growth.
High throughput in the development process, perfusion chromatography, usage of data analytics and affinity chromatography are some of the crucial developments in downstream processing. Furthermore, the advantages related to the single use technology like substantial reduction in the facility construction time and capital cost which shall accelerate the growth of the market. Other benefits like improves mobility, increased scalability, eliminating cross contamination risk, reduced demand for sterilization and cleaning and high productivity shall boost the demand for downstream method significantly. The key market players are initiating multiple research and development activities for cutting down the total production cost, thereby minimizing the cost of retail products. These activities have escalated the investments in biotech research, thereby shortening the time of processing and the scope of throughput.